Anzeige
Mehr »
Freitag, 02.01.2026 - Börsentäglich über 12.000 News
Schon +250% im Plus - warum diese Goldstory gerade erst startet!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z8N | ISIN: US62818Q3020 | Ticker-Symbol: 2W6
NASDAQ
31.12.25 | 21:48
0,980 US-Dollar
+3,16 % +0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MUSTANG BIO INC Chart 1 Jahr
5-Tage-Chart
MUSTANG BIO INC 5-Tage-Chart

Aktuelle News zur MUSTANG BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.12.25MUSTANG BIO, INC. - 8-K, Current Report-
07.11.25MUSTANG BIO, INC. - 10-Q, Quarterly Report-
08.08.25MUSTANG BIO, INC. - 10-Q, Quarterly Report4
09.07.25Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio987OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at...
► Artikel lesen
08.07.25MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy2
07.07.25Mustang Bio Stock Soars 200% On FDA Orphan Drug Designation10
07.07.25Dow Dips 1%; Mustang Bio Shares Spike Higher2
07.07.25Mustang Bio rises after FDA orphan drug status for MB-1017
MUSTANG BIO Aktie jetzt für 0€ handeln
07.07.25Mustang Bio-Aktie steigt stark an nach FDA-Sonderstatus für Hirntumor-Therapie20
07.07.25Mustang Bio stock soars after FDA grants orphan drug designation1
07.07.25FDA grants orphan drug status to Mustang Bio's glioma treatment8
07.07.25Mustang Bio, Inc.: Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma378In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting...
► Artikel lesen
05.03.25Mustang Bio, Inc.: Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement256WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq")...
► Artikel lesen
27.02.25Mustang Bio, Inc.: Mustang Bio Announces Sale of Fixed Assets and Exit of Facility615WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs...
► Artikel lesen
11.02.25Mustang Bio, Inc.: Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement271WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq")...
► Artikel lesen
14.01.25Mustang Bio, Inc.: Mustang Bio Announces Reverse Stock Split183WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1